Anebulo Pharmaceuticals, Inc.
ANEB
$1.14
$0.065.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.96% | -24.47% | -23.02% | -21.37% | 5.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.92% | -30.20% | -29.49% | -18.53% | 0.30% |
| Operating Income | 24.92% | 30.20% | 29.49% | 18.53% | -0.30% |
| Income Before Tax | 26.92% | 31.72% | 30.09% | 19.14% | 1.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.92% | 31.72% | 30.09% | 19.14% | 1.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.92% | 31.72% | 30.09% | 19.14% | 1.37% |
| EBIT | 24.92% | 30.20% | 29.49% | 18.53% | -0.30% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 28.91% | 32.36% | 31.94% | 22.60% | 7.24% |
| Normalized Basic EPS | 28.90% | 32.36% | 31.92% | 22.60% | 7.26% |
| EPS Diluted | 28.91% | 32.36% | 31.94% | 22.60% | 7.24% |
| Normalized Diluted EPS | 28.90% | 32.36% | 31.92% | 22.60% | 7.26% |
| Average Basic Shares Outstanding | 2.46% | 1.03% | 2.96% | 5.06% | 7.26% |
| Average Diluted Shares Outstanding | 2.46% | 1.03% | 2.96% | 5.06% | 7.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |